Cargando…

A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis

A systems model was developed to describe the metabolism and disposition of ursodeoxycholic acid (UDCA) and its conjugates in healthy subjects based on pharmacokinetic (PK) data from published studies in order to study the distribution of oral UDCA and potential interactions influencing therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zuo, P, Dobbins, RL, O'Connor‐Semmes, RL, Young, MA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999605/ https://www.ncbi.nlm.nih.gov/pubmed/27537780 http://dx.doi.org/10.1002/psp4.12100

Ejemplares similares

Ursodeoxycholic Acid Improves Bilirubin but Not Albumin in Primary Biliary Cirrhosis: Further Evidence for Nonefficacy
por: Tsochatzis, Emmanuel A., et al.
Publicado: (2013)

A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis
por: Wang, Lu, et al.
Publicado: (2015)

Combination Therapy of Ursodeoxycholic Acid and Corticosteroids for Primary Biliary Cirrhosis with Features of Autoimmune Hepatitis: A Meta-Analysis
por: Zhang, Yan, et al.
Publicado: (2013)

Treatment of primary biliary cirrhosis with ursodeoxycholic acid combined with traditional Chinese medicine: A protocol for systematic review and meta analysis
por: Chen, Xing, et al.
Publicado: (2020)

Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis
por: Shu, Yanyun, et al.
Publicado: (2021)

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis
por: Martinez-Gili, Laura, et al.
Publicado: (2023)

The Association between Bile Salt Export Pump Single-Nucleotide Polymorphisms and Primary Biliary Cirrhosis Susceptibility and Ursodeoxycholic Acid Response
por: Chen, Rui-rui, et al.
Publicado: (2014)

Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review
por: Li, Xuan, et al.
Publicado: (2020)

Ursodeoxycholic Acid Influences the Expression of p27(kip1) but Not FoxO1 in Patients with Non-Cirrhotic Primary Biliary Cirrhosis
por: Milkiewicz, Malgorzata, et al.
Publicado: (2014)

Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis
por: Zhang, Yan, et al.
Publicado: (2015)

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study
por: Cançado, Guilherme Grossi Lopes, et al.
Publicado: (2022)

Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis
por: Zimmer, Vincent, et al.
Publicado: (2016)

External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: Cheung, Angela C., et al.
Publicado: (2018)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)

Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study
por: Papastergiou, V, et al.
Publicado: (2013)

Case–Control Study on Prednisolone Combined With Ursodeoxycholic Acid and Azathioprine in Pure Primary Biliary Cirrhosis With High Levels of Immunoglobulin G and Transaminases: Efficacy and Safety Analysis
por: Fang, Yu-Qing, et al.
Publicado: (2014)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis
por: Wang, Zi-Long, et al.
Publicado: (2022)

A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid
por: Li, Chunlei, et al.
Publicado: (2022)

Primary biliary cirrhosis
por: Kumagi, Teru, et al.
Publicado: (2008)

Primary biliary cirrhosis
por: Hohenester, Simon, et al.
Publicado: (2009)

Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects
por: Murakami, Masanori, et al.
Publicado: (2013)

Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials
por: Agrawal, Rohit, et al.
Publicado: (2019)

A 60-Year-Old Woman with Primary Biliary Cholangitis and Crohn’s Ileitis Following the Suspension of Ursodeoxycholic Acid
por: Romeo, Mario, et al.
Publicado: (2022)

Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid
por: Ding, Dawei, et al.
Publicado: (2022)

Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion
por: Yang, Chunmei, et al.
Publicado: (2022)

Efficacy of ursodeoxycholic acid for primary biliary cholangitis: Experience from a tertiary care centre in Saudi Arabia
por: AlWabel, Ahmed H, et al.
Publicado: (2022)

Ursodeoxycholic Acid Is Conjugated with Taurine to Promote Secretin-Stimulated Biliary Hydrocholeresis in the Normal Rat
por: Úriz, Miriam, et al.
Publicado: (2011)

Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis
por: Ni, Ping, et al.
Publicado: (2019)

Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease
por: Cortez‐Pinto, Helena, et al.
Publicado: (2021)

Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients
por: Wang, Zi-Long, et al.
Publicado: (2022)

Biliary secretion of endotoxin and pathogenesis of primary biliary cirrhosis.
por: Sakisaka, S., et al.
Publicado: (1997)

Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid
por: Cheung, Ka-Shing, et al.
Publicado: (2017)

Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis
por: Xiang, Xinyu, et al.
Publicado: (2021)

Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: de Veer, Rozanne C., et al.
Publicado: (2022)

Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis
por: de Veer, Rozanne C., et al.
Publicado: (2023)

Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study
por: Chang, Jong-In, et al.
Publicado: (2023)

Geographic Clusters of Primary Biliary Cirrhosis
por: Abu-Mouch, Saif, et al.
Publicado: (2003)

The diagnosis and treatment of primary biliary cirrhosis
por: Kim, Kyung-Ah, et al.
Publicado: (2011)

Primary Biliary Cirrhosis: Family Stories
por: Smyk, Daniel, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_qmqhk5426921fgpne2gi3584h9